milliplex ® map multiplex panels Search Results


milliplex map human cytokine/chemokine/growth factor panel a – immunology multiplex assay  (Merck & Co)
90
Merck & Co milliplex map human cytokine/chemokine/growth factor panel a – immunology multiplex assay
RNA sequencing reveals few differences between NF1 -mutant and CTL hiMGL cells, whereas the induced secretome remains unchanged. (A) Principal component analysis (PCA) plot generated from RNA sequencing data (CTL, blue; M1, red; M3, yellow). (B) Heatmap showing unsupervised hierarchical clustering generated from RNA sequencing data for CTL, M1 and M3 hiMGL cells. (C,D) Volcano plot demonstrating genes differentially expressed between M1 versus M3 (C) or between M1 and M3 versus CTL (D) (FDR<0.05, fold change cutoff of −5 and 5). Grey dots indicate genes with no change (N/C) in expression, blue dots indicate genes with decreased expression and red dots indicate genes with increased expression. (E) Relative mRNA expression (R.E.) of Toll-like receptor 4 ( TLR4 ) in CTL and NF1 -mutant (M1-M3) hiMGL cells by quantitative RT-PCR. Gene expression levels are shown relative to expression in CTL hiMGL cells. The housekeeping gene TBP was used for normalization ( n =3). Data were normalized to TLR4 expression levels in CTL hiMGL cells. Results are represented as the mean±s.e.m. Data were analyzed by one-way ANOVA. (F) Multiplex immunoassay was used to detect TNF-α (left) and IL-6 (right) in supernatants from CTL and NF1 -mutant (M1-M3) hiMGL cells in response to 1 μg/ml LPS stimulation for 24 h (n=3-4). Data between basal and LPS conditions were analyzed using two-tailed unpaired t -tests. Results are represented as the mean±s.e.m. <t>Cytokine</t> release under basal or LPS conditions was not significantly different between CTL and M1, M2 and M3 hiMGL cells (one-way ANOVA). The data showing the release of additional cytokines are included in <xref ref-type=Fig. S4 . n.s., not significant; * P <0.05; ** P <0.01; *** P <0.001. " width="250" height="auto" />
Milliplex Map Human Cytokine/Chemokine/Growth Factor Panel A – Immunology Multiplex Assay, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/milliplex map human cytokine/chemokine/growth factor panel a – immunology multiplex assay/product/Merck & Co
Average 90 stars, based on 1 article reviews
milliplex map human cytokine/chemokine/growth factor panel a – immunology multiplex assay - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human neurodegenerative panel 1 (7-plex) cat. hndg1-36k milliplex map multiplex panels  (Merck KGaA)
90
Merck KGaA human neurodegenerative panel 1 (7-plex) cat. hndg1-36k milliplex map multiplex panels
RNA sequencing reveals few differences between NF1 -mutant and CTL hiMGL cells, whereas the induced secretome remains unchanged. (A) Principal component analysis (PCA) plot generated from RNA sequencing data (CTL, blue; M1, red; M3, yellow). (B) Heatmap showing unsupervised hierarchical clustering generated from RNA sequencing data for CTL, M1 and M3 hiMGL cells. (C,D) Volcano plot demonstrating genes differentially expressed between M1 versus M3 (C) or between M1 and M3 versus CTL (D) (FDR<0.05, fold change cutoff of −5 and 5). Grey dots indicate genes with no change (N/C) in expression, blue dots indicate genes with decreased expression and red dots indicate genes with increased expression. (E) Relative mRNA expression (R.E.) of Toll-like receptor 4 ( TLR4 ) in CTL and NF1 -mutant (M1-M3) hiMGL cells by quantitative RT-PCR. Gene expression levels are shown relative to expression in CTL hiMGL cells. The housekeeping gene TBP was used for normalization ( n =3). Data were normalized to TLR4 expression levels in CTL hiMGL cells. Results are represented as the mean±s.e.m. Data were analyzed by one-way ANOVA. (F) Multiplex immunoassay was used to detect TNF-α (left) and IL-6 (right) in supernatants from CTL and NF1 -mutant (M1-M3) hiMGL cells in response to 1 μg/ml LPS stimulation for 24 h (n=3-4). Data between basal and LPS conditions were analyzed using two-tailed unpaired t -tests. Results are represented as the mean±s.e.m. <t>Cytokine</t> release under basal or LPS conditions was not significantly different between CTL and M1, M2 and M3 hiMGL cells (one-way ANOVA). The data showing the release of additional cytokines are included in <xref ref-type=Fig. S4 . n.s., not significant; * P <0.05; ** P <0.01; *** P <0.001. " width="250" height="auto" />
Human Neurodegenerative Panel 1 (7 Plex) Cat. Hndg1 36k Milliplex Map Multiplex Panels, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human neurodegenerative panel 1 (7-plex) cat. hndg1-36k milliplex map multiplex panels/product/Merck KGaA
Average 90 stars, based on 1 article reviews
human neurodegenerative panel 1 (7-plex) cat. hndg1-36k milliplex map multiplex panels - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
milliplex map human oxidative phosphorylation (oxphos) magnetic bead panel-cellular metabolism multiplex assay  (Merck KGaA)
90
Merck KGaA milliplex map human oxidative phosphorylation (oxphos) magnetic bead panel-cellular metabolism multiplex assay
RNA sequencing reveals few differences between NF1 -mutant and CTL hiMGL cells, whereas the induced secretome remains unchanged. (A) Principal component analysis (PCA) plot generated from RNA sequencing data (CTL, blue; M1, red; M3, yellow). (B) Heatmap showing unsupervised hierarchical clustering generated from RNA sequencing data for CTL, M1 and M3 hiMGL cells. (C,D) Volcano plot demonstrating genes differentially expressed between M1 versus M3 (C) or between M1 and M3 versus CTL (D) (FDR<0.05, fold change cutoff of −5 and 5). Grey dots indicate genes with no change (N/C) in expression, blue dots indicate genes with decreased expression and red dots indicate genes with increased expression. (E) Relative mRNA expression (R.E.) of Toll-like receptor 4 ( TLR4 ) in CTL and NF1 -mutant (M1-M3) hiMGL cells by quantitative RT-PCR. Gene expression levels are shown relative to expression in CTL hiMGL cells. The housekeeping gene TBP was used for normalization ( n =3). Data were normalized to TLR4 expression levels in CTL hiMGL cells. Results are represented as the mean±s.e.m. Data were analyzed by one-way ANOVA. (F) Multiplex immunoassay was used to detect TNF-α (left) and IL-6 (right) in supernatants from CTL and NF1 -mutant (M1-M3) hiMGL cells in response to 1 μg/ml LPS stimulation for 24 h (n=3-4). Data between basal and LPS conditions were analyzed using two-tailed unpaired t -tests. Results are represented as the mean±s.e.m. <t>Cytokine</t> release under basal or LPS conditions was not significantly different between CTL and M1, M2 and M3 hiMGL cells (one-way ANOVA). The data showing the release of additional cytokines are included in <xref ref-type=Fig. S4 . n.s., not significant; * P <0.05; ** P <0.01; *** P <0.001. " width="250" height="auto" />
Milliplex Map Human Oxidative Phosphorylation (Oxphos) Magnetic Bead Panel Cellular Metabolism Multiplex Assay, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/milliplex map human oxidative phosphorylation (oxphos) magnetic bead panel-cellular metabolism multiplex assay/product/Merck KGaA
Average 90 stars, based on 1 article reviews
milliplex map human oxidative phosphorylation (oxphos) magnetic bead panel-cellular metabolism multiplex assay - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
elisa techniques milliplex map rat metabolic hormone panel-metabolism multiplex assay (rmhmag-84k)  (Merck KGaA)
90
Merck KGaA elisa techniques milliplex map rat metabolic hormone panel-metabolism multiplex assay (rmhmag-84k)
RNA sequencing reveals few differences between NF1 -mutant and CTL hiMGL cells, whereas the induced secretome remains unchanged. (A) Principal component analysis (PCA) plot generated from RNA sequencing data (CTL, blue; M1, red; M3, yellow). (B) Heatmap showing unsupervised hierarchical clustering generated from RNA sequencing data for CTL, M1 and M3 hiMGL cells. (C,D) Volcano plot demonstrating genes differentially expressed between M1 versus M3 (C) or between M1 and M3 versus CTL (D) (FDR<0.05, fold change cutoff of −5 and 5). Grey dots indicate genes with no change (N/C) in expression, blue dots indicate genes with decreased expression and red dots indicate genes with increased expression. (E) Relative mRNA expression (R.E.) of Toll-like receptor 4 ( TLR4 ) in CTL and NF1 -mutant (M1-M3) hiMGL cells by quantitative RT-PCR. Gene expression levels are shown relative to expression in CTL hiMGL cells. The housekeeping gene TBP was used for normalization ( n =3). Data were normalized to TLR4 expression levels in CTL hiMGL cells. Results are represented as the mean±s.e.m. Data were analyzed by one-way ANOVA. (F) Multiplex immunoassay was used to detect TNF-α (left) and IL-6 (right) in supernatants from CTL and NF1 -mutant (M1-M3) hiMGL cells in response to 1 μg/ml LPS stimulation for 24 h (n=3-4). Data between basal and LPS conditions were analyzed using two-tailed unpaired t -tests. Results are represented as the mean±s.e.m. <t>Cytokine</t> release under basal or LPS conditions was not significantly different between CTL and M1, M2 and M3 hiMGL cells (one-way ANOVA). The data showing the release of additional cytokines are included in <xref ref-type=Fig. S4 . n.s., not significant; * P <0.05; ** P <0.01; *** P <0.001. " width="250" height="auto" />
Elisa Techniques Milliplex Map Rat Metabolic Hormone Panel Metabolism Multiplex Assay (Rmhmag 84k), supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa techniques milliplex map rat metabolic hormone panel-metabolism multiplex assay (rmhmag-84k)/product/Merck KGaA
Average 90 stars, based on 1 article reviews
elisa techniques milliplex map rat metabolic hormone panel-metabolism multiplex assay (rmhmag-84k) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
protocol booklet for milliplex® map human cytokine/ chemokine magnetic bead panel-immunology multiplex assay  (Merck KGaA)
90
Merck KGaA protocol booklet for milliplex® map human cytokine/ chemokine magnetic bead panel-immunology multiplex assay
RNA sequencing reveals few differences between NF1 -mutant and CTL hiMGL cells, whereas the induced secretome remains unchanged. (A) Principal component analysis (PCA) plot generated from RNA sequencing data (CTL, blue; M1, red; M3, yellow). (B) Heatmap showing unsupervised hierarchical clustering generated from RNA sequencing data for CTL, M1 and M3 hiMGL cells. (C,D) Volcano plot demonstrating genes differentially expressed between M1 versus M3 (C) or between M1 and M3 versus CTL (D) (FDR<0.05, fold change cutoff of −5 and 5). Grey dots indicate genes with no change (N/C) in expression, blue dots indicate genes with decreased expression and red dots indicate genes with increased expression. (E) Relative mRNA expression (R.E.) of Toll-like receptor 4 ( TLR4 ) in CTL and NF1 -mutant (M1-M3) hiMGL cells by quantitative RT-PCR. Gene expression levels are shown relative to expression in CTL hiMGL cells. The housekeeping gene TBP was used for normalization ( n =3). Data were normalized to TLR4 expression levels in CTL hiMGL cells. Results are represented as the mean±s.e.m. Data were analyzed by one-way ANOVA. (F) Multiplex immunoassay was used to detect TNF-α (left) and IL-6 (right) in supernatants from CTL and NF1 -mutant (M1-M3) hiMGL cells in response to 1 μg/ml LPS stimulation for 24 h (n=3-4). Data between basal and LPS conditions were analyzed using two-tailed unpaired t -tests. Results are represented as the mean±s.e.m. <t>Cytokine</t> release under basal or LPS conditions was not significantly different between CTL and M1, M2 and M3 hiMGL cells (one-way ANOVA). The data showing the release of additional cytokines are included in <xref ref-type=Fig. S4 . n.s., not significant; * P <0.05; ** P <0.01; *** P <0.001. " width="250" height="auto" />
Protocol Booklet For Milliplex® Map Human Cytokine/ Chemokine Magnetic Bead Panel Immunology Multiplex Assay, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protocol booklet for milliplex® map human cytokine/ chemokine magnetic bead panel-immunology multiplex assay/product/Merck KGaA
Average 90 stars, based on 1 article reviews
protocol booklet for milliplex® map human cytokine/ chemokine magnetic bead panel-immunology multiplex assay - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
multiplex commercial assay milliplex® map human cytokine/ chemokine magnetic bead panel, hcytomag-60 k  (Merck KGaA)
90
Merck KGaA multiplex commercial assay milliplex® map human cytokine/ chemokine magnetic bead panel, hcytomag-60 k
RNA sequencing reveals few differences between NF1 -mutant and CTL hiMGL cells, whereas the induced secretome remains unchanged. (A) Principal component analysis (PCA) plot generated from RNA sequencing data (CTL, blue; M1, red; M3, yellow). (B) Heatmap showing unsupervised hierarchical clustering generated from RNA sequencing data for CTL, M1 and M3 hiMGL cells. (C,D) Volcano plot demonstrating genes differentially expressed between M1 versus M3 (C) or between M1 and M3 versus CTL (D) (FDR<0.05, fold change cutoff of −5 and 5). Grey dots indicate genes with no change (N/C) in expression, blue dots indicate genes with decreased expression and red dots indicate genes with increased expression. (E) Relative mRNA expression (R.E.) of Toll-like receptor 4 ( TLR4 ) in CTL and NF1 -mutant (M1-M3) hiMGL cells by quantitative RT-PCR. Gene expression levels are shown relative to expression in CTL hiMGL cells. The housekeeping gene TBP was used for normalization ( n =3). Data were normalized to TLR4 expression levels in CTL hiMGL cells. Results are represented as the mean±s.e.m. Data were analyzed by one-way ANOVA. (F) Multiplex immunoassay was used to detect TNF-α (left) and IL-6 (right) in supernatants from CTL and NF1 -mutant (M1-M3) hiMGL cells in response to 1 μg/ml LPS stimulation for 24 h (n=3-4). Data between basal and LPS conditions were analyzed using two-tailed unpaired t -tests. Results are represented as the mean±s.e.m. <t>Cytokine</t> release under basal or LPS conditions was not significantly different between CTL and M1, M2 and M3 hiMGL cells (one-way ANOVA). The data showing the release of additional cytokines are included in <xref ref-type=Fig. S4 . n.s., not significant; * P <0.05; ** P <0.01; *** P <0.001. " width="250" height="auto" />
Multiplex Commercial Assay Milliplex® Map Human Cytokine/ Chemokine Magnetic Bead Panel, Hcytomag 60 K, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multiplex commercial assay milliplex® map human cytokine/ chemokine magnetic bead panel, hcytomag-60 k/product/Merck KGaA
Average 90 stars, based on 1 article reviews
multiplex commercial assay milliplex® map human cytokine/ chemokine magnetic bead panel, hcytomag-60 k - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
milliplex map rat vascular injury magnetic bead panel 3— toxicity multiplex assay  (Merck KGaA)
90
Merck KGaA milliplex map rat vascular injury magnetic bead panel 3— toxicity multiplex assay
RNA sequencing reveals few differences between NF1 -mutant and CTL hiMGL cells, whereas the induced secretome remains unchanged. (A) Principal component analysis (PCA) plot generated from RNA sequencing data (CTL, blue; M1, red; M3, yellow). (B) Heatmap showing unsupervised hierarchical clustering generated from RNA sequencing data for CTL, M1 and M3 hiMGL cells. (C,D) Volcano plot demonstrating genes differentially expressed between M1 versus M3 (C) or between M1 and M3 versus CTL (D) (FDR<0.05, fold change cutoff of −5 and 5). Grey dots indicate genes with no change (N/C) in expression, blue dots indicate genes with decreased expression and red dots indicate genes with increased expression. (E) Relative mRNA expression (R.E.) of Toll-like receptor 4 ( TLR4 ) in CTL and NF1 -mutant (M1-M3) hiMGL cells by quantitative RT-PCR. Gene expression levels are shown relative to expression in CTL hiMGL cells. The housekeeping gene TBP was used for normalization ( n =3). Data were normalized to TLR4 expression levels in CTL hiMGL cells. Results are represented as the mean±s.e.m. Data were analyzed by one-way ANOVA. (F) Multiplex immunoassay was used to detect TNF-α (left) and IL-6 (right) in supernatants from CTL and NF1 -mutant (M1-M3) hiMGL cells in response to 1 μg/ml LPS stimulation for 24 h (n=3-4). Data between basal and LPS conditions were analyzed using two-tailed unpaired t -tests. Results are represented as the mean±s.e.m. <t>Cytokine</t> release under basal or LPS conditions was not significantly different between CTL and M1, M2 and M3 hiMGL cells (one-way ANOVA). The data showing the release of additional cytokines are included in <xref ref-type=Fig. S4 . n.s., not significant; * P <0.05; ** P <0.01; *** P <0.001. " width="250" height="auto" />
Milliplex Map Rat Vascular Injury Magnetic Bead Panel 3— Toxicity Multiplex Assay, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/milliplex map rat vascular injury magnetic bead panel 3— toxicity multiplex assay/product/Merck KGaA
Average 90 stars, based on 1 article reviews
milliplex map rat vascular injury magnetic bead panel 3— toxicity multiplex assay - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


RNA sequencing reveals few differences between NF1 -mutant and CTL hiMGL cells, whereas the induced secretome remains unchanged. (A) Principal component analysis (PCA) plot generated from RNA sequencing data (CTL, blue; M1, red; M3, yellow). (B) Heatmap showing unsupervised hierarchical clustering generated from RNA sequencing data for CTL, M1 and M3 hiMGL cells. (C,D) Volcano plot demonstrating genes differentially expressed between M1 versus M3 (C) or between M1 and M3 versus CTL (D) (FDR<0.05, fold change cutoff of −5 and 5). Grey dots indicate genes with no change (N/C) in expression, blue dots indicate genes with decreased expression and red dots indicate genes with increased expression. (E) Relative mRNA expression (R.E.) of Toll-like receptor 4 ( TLR4 ) in CTL and NF1 -mutant (M1-M3) hiMGL cells by quantitative RT-PCR. Gene expression levels are shown relative to expression in CTL hiMGL cells. The housekeeping gene TBP was used for normalization ( n =3). Data were normalized to TLR4 expression levels in CTL hiMGL cells. Results are represented as the mean±s.e.m. Data were analyzed by one-way ANOVA. (F) Multiplex immunoassay was used to detect TNF-α (left) and IL-6 (right) in supernatants from CTL and NF1 -mutant (M1-M3) hiMGL cells in response to 1 μg/ml LPS stimulation for 24 h (n=3-4). Data between basal and LPS conditions were analyzed using two-tailed unpaired t -tests. Results are represented as the mean±s.e.m. Cytokine release under basal or LPS conditions was not significantly different between CTL and M1, M2 and M3 hiMGL cells (one-way ANOVA). The data showing the release of additional cytokines are included in <xref ref-type=Fig. S4 . n.s., not significant; * P <0.05; ** P <0.01; *** P <0.001. " width="100%" height="100%">

Journal: Disease Models & Mechanisms

Article Title: Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia

doi: 10.1242/dmm.049861

Figure Lengend Snippet: RNA sequencing reveals few differences between NF1 -mutant and CTL hiMGL cells, whereas the induced secretome remains unchanged. (A) Principal component analysis (PCA) plot generated from RNA sequencing data (CTL, blue; M1, red; M3, yellow). (B) Heatmap showing unsupervised hierarchical clustering generated from RNA sequencing data for CTL, M1 and M3 hiMGL cells. (C,D) Volcano plot demonstrating genes differentially expressed between M1 versus M3 (C) or between M1 and M3 versus CTL (D) (FDR<0.05, fold change cutoff of −5 and 5). Grey dots indicate genes with no change (N/C) in expression, blue dots indicate genes with decreased expression and red dots indicate genes with increased expression. (E) Relative mRNA expression (R.E.) of Toll-like receptor 4 ( TLR4 ) in CTL and NF1 -mutant (M1-M3) hiMGL cells by quantitative RT-PCR. Gene expression levels are shown relative to expression in CTL hiMGL cells. The housekeeping gene TBP was used for normalization ( n =3). Data were normalized to TLR4 expression levels in CTL hiMGL cells. Results are represented as the mean±s.e.m. Data were analyzed by one-way ANOVA. (F) Multiplex immunoassay was used to detect TNF-α (left) and IL-6 (right) in supernatants from CTL and NF1 -mutant (M1-M3) hiMGL cells in response to 1 μg/ml LPS stimulation for 24 h (n=3-4). Data between basal and LPS conditions were analyzed using two-tailed unpaired t -tests. Results are represented as the mean±s.e.m. Cytokine release under basal or LPS conditions was not significantly different between CTL and M1, M2 and M3 hiMGL cells (one-way ANOVA). The data showing the release of additional cytokines are included in Fig. S4 . n.s., not significant; * P <0.05; ** P <0.01; *** P <0.001.

Article Snippet: The MILLIPLEX MAP human cytokine/chemokine/growth factor panel A – immunology multiplex assay (HCYTA-60K, Merck) was used according to the manufacturer's recommendations.

Techniques: RNA Sequencing Assay, Mutagenesis, Generated, Expressing, Quantitative RT-PCR, Multiplex Assay, Two Tailed Test